Tylenol autism lawsuit claims continue to evolve as families seek accountability for prenatal acetaminophen exposure. Thousands of parents allege that taking Tylenol or generic acetaminophen during pregnancy contributed to their children developing autism spectrum disorder or ADHD. The federal multidistrict litigation, known as MDL 3043, is currently on appeal before the Second Circuit Court of Appeals. As of May 2026, no settlements have been reached. However, new state-level actions and an FDA safety notice have kept this litigation alive and closely watched.
Case Timeline
Last checked: July 11, 2026
Advertisement
February 26, 2026: Judge rejects Kenvue bid to dismiss Texas lawsuit over Tylenol safety – Reuters (Reuters)
July 10, 2026 (Bellwether Date): No bellwether trials have been scheduled in MDL-3043; the court awaits the Second Circuit appellate ruling, which must reverse the Daubert dismissal before any federal bellwether trials can be set. (Court Record)
July 10, 2026 (Settlement): No settlement has been reached and no global settlement framework announced; projections cited range $50,000–$500,000+ per claim, with a possible global deal contingent on a 2026 appellate reversal and more likely in 2027. (Court Record)
July 10, 2026 (Case Status): Texas state court Judge LeAnn Rafferty denied Kenvue/J&J’s motion to dismiss the Texas AG (Paxton) suit, and new state-court cases were filed in Illinois, Florida, and Pennsylvania. (Court Record)
July 09, 2026: Study Reveals No Link Between Prenatal Acetaminophen and Autism or ADHD in Offspring – HealthDay (HealthDay)
July 09, 2026: No Link Between Prenatal Tylenol Use and Autism, ADHD, Multiple Studies Confirm – Healthline (Healthline)
July 06, 2026: Major study finds no link between Tylenol use in pregnancy and autism – cbs19.tv (cbs19.tv)
July 06, 2026: Tylenol During Pregnancy Does Not Cause Autism or ADHD, Massive Sibling Study Finds – StudyFinds (StudyFinds)
July 03, 2026 (Ruling): As of April 2026, Judge Denise L. Cote granted summary judgment, effectively ending the federal Tylenol autism MDL, though this remains subject to the pending Second Circuit appeal. (Court Record)
July 03, 2026 (Bellwether Date): No bellwether trials have been scheduled; they remain contingent on the Second Circuit reversing Judge Cote’s exclusion of plaintiffs’ general-causation experts, with trials only possible later in 2026 if the dismissal is overturned. (Court Record)
July 03, 2026 (Settlement): No settlement framework has been announced and no settlements have been reached with manufacturers; a global settlement is not viewed as possible until 2027 at the earliest and only if the appeal succeeds. (Court Record)
July 03, 2026 (Case Status): State-court litigation continues to advance as Judge LeAnn Rafferty denied Kenvue and Johnson & Johnson’s motion to dismiss the Texas AG (Paxton) lawsuit, with new cases filed in Pennsylvania, Florida, and Illinois. (Court Record)
July 01, 2026: Should pregnant women worry about taking Tylenol? 20-year sibling-matched study finds no link to autism or ADHD – Medical Xpress (Medical Xpress)
July 01, 2026: Study Finds No Link Between Prenatal Acetaminophen Use and Autism, ADHD – Drug Topics (Drug Topics)
June 30, 2026: Major study finds no link between acetaminophen use during pregnancy, autism – cbs19.tv (cbs19.tv)
June 29, 2026: Acetaminophen in pregnancy shows no link to autism or ADHD, again – Science News (Science News)
June 29, 2026: Study Suggests No Link Between Prenatal Tylenol and Risks for Autism, ADHD – MedPage Today (MedPage Today)
June 29, 2026: Tylenol during pregnancy doesn’t increase risk of child’s autism or ADHD, study suggests – CIDRAP (CIDRAP)
June 26, 2026 (Ruling): The Second Circuit Court of Appeals heard oral arguments on November 17, 2025 on whether to revive the dismissed MDL, and a decision in 2026 will determine if the litigation reopens. (Court Record)
June 26, 2026 (Ruling): Judge Denise L. Cote granted summary judgment for defendants (following her 2023 Daubert exclusion of plaintiffs’ causation experts), and plaintiffs have appealed. (Court Record)
June 26, 2026 (Case Status): The federal MDL grew by 58 cases in one month to 441 pending cases, while new state-level suits are being filed in Illinois, Florida, and Pennsylvania. (Court Record)
June 26, 2026 (Ruling): Judge LeAnn Rafferty denied Kenvue and Johnson & Johnson’s motion to dismiss the lawsuit filed by Texas Attorney General Ken Paxton. (Court Record)
June 26, 2026 (Settlement): No settlements have been reached with manufacturers; a global settlement is only considered possible in 2027 and contingent on the Second Circuit appeal outcome. (Court Record)
June 26, 2026 (Bellwether Date): No bellwether trial dates have been formally set; trials could begin in late 2026 only if the Second Circuit reinstates the excluded expert testimony. (Court Record)
June 17, 2026: White House autism announcement triggers surge in online searches for leucovorin, Tylenol – CIDRAP (CIDRAP)
April 14, 2026: Danish study finds acetaminophen exposure not associated with increased autism risk – Contemporary OB/GYN (Contemporary OB/GYN)
June 12, 2026 (Ruling): Second Circuit Court of Appeals heard oral arguments on Nov 17, 2025 regarding reversal of Judge Cote’s Daubert ruling that excluded all plaintiffs’ causation experts; decision still pending as of June 2026. (Court Record)
June 12, 2026 (Ruling): Judge Cote granted summary judgment ending the federal MDL after her Sept 2024 Daubert ruling barred plaintiff expert witnesses from testifying that prenatal acetaminophen causes autism/ADHD. (Court Record)
June 12, 2026 (Ruling): Judge LeAnn Rafferty denied Kenvue/J&J motion to dismiss the Texas Attorney General lawsuit filed by Ken Paxton over Tylenol autism claims. (Court Record)
June 12, 2026 (Bellwether Date): No bellwether trial dates scheduled — federal MDL effectively halted pending Second Circuit appellate decision on the Daubert exclusion. (Court Record)
June 12, 2026 (Settlement): No settlement framework announced; settlements have been modest with confidentiality restrictions and filing trends have flatlined with low settlement velocity. (Court Record)
June 12, 2026 (Case Status): With federal MDL stalled, plaintiffs are filing new state court lawsuits in California, Illinois, Florida, Pennsylvania, Delaware, and New Jersey as alternative litigation path. (Court Record)
June 12, 2026 (Other): The pivotal 2026 event is the Second Circuit ruling — if reversed, the MDL reopens and could lead to bellwether trials; if upheld, litigation shifts permanently to state courts. (Court Record)
January 16, 2026: Tylenol use during pregnancy not linked to autism, new study says – statnews.com (statnews.com)
February 11, 2026: Federal judge says research can’t be used to link acetaminophen to autism, ADHD – ABC News – Breaking News, Latest News and Videos (ABC News – Breaking News, Latest News and Videos)
June 05, 2026 (Ruling): In January 2026, Judge Denise L. Cote granted summary judgment in favor of defendants (Kenvue/J&J), effectively ending federal MDL-3043 litigation; plaintiffs have appealed to the Second Circuit. (Court Record)
June 05, 2026 (Ruling): The Second Circuit heard oral arguments on November 17, 2025, with appellate judges reportedly signaling doubts about the lower court’s dismissal of plaintiffs’ expert witnesses. (Court Record)
June 05, 2026 (Case Status): The Second Circuit appeal decision remains pending as of June 2026 — this is the pivotal ruling that will determine whether the federal MDL is revived or permanently closed. (Court Record)
June 05, 2026 (Bellwether Date): No bellwether trial dates are currently scheduled; trials could only be set if the Second Circuit reverses the summary judgment and reopens the MDL. (Court Record)
June 05, 2026 (Settlement): No settlement framework has been announced; plaintiff attorneys project potential settlement values of $300,000–$600,000 per case if litigation proceeds. (Court Record)
June 05, 2026 (Ruling): In Texas state court, Judge LeAnn Rafferty denied Kenvue/J&J’s motion to dismiss the Texas Attorney General’s lawsuit, keeping that state-level case alive. (Court Record)
June 05, 2026 (Other): The FDA has initiated a label update for acetaminophen products to include information about autism and ADHD risk, which could strengthen plaintiffs’ causation arguments. (Court Record)
June 05, 2026 (Case Status): State-level lawsuits continue to be filed in Illinois, Florida, and Pennsylvania independent of the federal MDL outcome. (Court Record)
June 03, 2026: New medical guidance affirms Tylenol safety during pregnancy months after Trump sows doubt – Stateline (Stateline)
June 02, 2026: CMAJ: Acetaminophen in pregnancy – Avian Flu Diary (Avian Flu Diary)
June 02, 2026: Pregnancy & Tylenol: The Truth Behind the Mistaken Association – Psychiatric Times (Psychiatric Times)
May 27, 2026: Texas AG Blocks Kenvue Dividend Over Tylenol Autism Lawsuit Scandal Keaton Wagler (VepgInOB6D) – Mshale (Mshale)
October 28, 2025: Texas Sues Tylenol Makers Over Claims of Links to Autism – Time Magazine (Time Magazine)
May 22, 2026 (Ruling): Second Circuit Court of Appeals heard oral arguments Nov 17, 2025 on reversing Judge Cote’s Daubert exclusion of all five plaintiffs’ causation experts; decision still pending as of May 2026. (Court Record)
May 22, 2026 (Ruling): Judge Cote’s September 2024 general causation ruling excluding plaintiff expert witnesses remains in effect, effectively stalling the federal MDL. (Court Record)
May 22, 2026 (Ruling): A judge denied Kenvue/J&J’s motion to dismiss the Texas Attorney General’s lawsuit against the companies over Tylenol autism claims. (Court Record)
May 22, 2026 (Bellwether Date): No bellwether trial dates scheduled; trials cannot proceed until the Second Circuit rules on the expert exclusion appeal. (Court Record)
May 22, 2026 (Settlement): No settlement framework announced; estimated individual settlement values range $50,000–$300,000+ if litigation proceeds favorably. (Court Record)
May 22, 2026 (Case Status): 58 new cases added to MDL-3043 in the last reporting period, bringing total pending cases to 441. (Court Record)
May 22, 2026 (Case Status): State court filings continuing in Illinois, Florida, Pennsylvania, California, New Jersey, and Delaware as alternative to stalled federal MDL. (Court Record)
May 22, 2026 (Other): FDA initiated a label update for Tylenol to include information on autism and ADHD risk. (Court Record)
May 15, 2026: Analysis Refutes Claims That Acetaminophen Use During Pregnancy Increases Risk of Autism – Neurology Today (Neurology Today)
January 20, 2026: No Link Between Acetaminophen in Pregnancy and Autism, a Study Finds – The New York Times (The New York Times)
May 18, 2026: Acetaminophen use down after FDA guidance changes – Delco Times (Delco Times)
May 15, 2026 (Ruling): Judge Denise L. Cote granted summary judgment in favor of defendants (January 2026), effectively ending the federal MDL-3043 litigation. (Court Record)
May 15, 2026 (Ruling): Plaintiffs have appealed the summary judgment to the Second Circuit Court of Appeals, which signaled it may reconsider whether expert testimony was excluded too broadly. (Court Record)
May 15, 2026 (Bellwether Date): No bellwether trials scheduled; trials contingent on Second Circuit reversing the Daubert/summary judgment rulings — potential for trials in late 2026 if appeal succeeds. (Court Record)
May 15, 2026 (Settlement): No global settlement reached; no settlement framework announced — negotiations projected to begin only if appellate court reverses dismissal. (Court Record)
May 15, 2026 (Case Status): State court lawsuits gaining momentum — Texas AG lawsuit survived motion to dismiss (Judge LeAnn Rafferty denied Kenvue/J&J dismissal motion); new cases filed in Illinois, Florida, and Pennsylvania. (Court Record)
May 15, 2026 (Other): FDA initiated label update for Tylenol to include autism/ADHD risk information for pregnant women, following Trump administration directive. (Court Record)
May 15, 2026 (Case Status): State court acetaminophen lawsuits expected to gain significant momentum in second half of 2026. (Court Record)
May 10, 2026: Is Tylenol (Acetaminophen) Linked to Increased Risk of Autism? – Britannica (Britannica)
What Is the Tylenol Autism Lawsuit About?
| MDL Detail |
Current Data |
| MDL Number |
MDL-3043 |
| Pending Cases |
58 |
| Presiding Judge |
Denise L. Cote |
| Federal District |
S.D.N.Y. |
| Data Source |
U.S. Judicial Panel on Multidistrict Litigation |
| Last Updated |
July 06, 2026 |
The Tylenol autism lawsuit centers on acetaminophen, the most widely used pain reliever during pregnancy. Plaintiffs allege that manufacturers knew about studies linking prenatal acetaminophen use to neurodevelopmental disorders. Despite this evidence, they continued marketing the product as safe for pregnant women. The primary defendants include Johnson & Johnson, its consumer health spinoff Kenvue Inc., and major retailers such as Walmart, CVS, Costco, and Target that sold store-brand versions.
Multiple scientific studies have examined this potential link. Research from Johns Hopkins found that children with the highest cord-blood acetaminophen levels were roughly three times more likely to receive an ADHD or autism diagnosis. A 2025 Mount Sinai systematic review of 46 studies and over 100,000 participants found elevated risk ratios. However, a large 2024 JAMA study of nearly 2.5 million Swedish births found no association when using sibling controls. The science remains genuinely contested.
Children allegedly affected have been diagnosed with autism spectrum disorder, ADHD, or both. In most cases, their mothers used acetaminophen regularly during pregnancy for pain or fever management. The injuries claimed include developmental delays, behavioral challenges, and lifelong care needs.
MDL Case Status and Key Facts
| Detail |
Information |
| MDL Number |
3043 |
| Full Title |
In Re: Acetaminophen — ASD/ADHD Products Liability Litigation |
| Presiding Judge |
Judge Denise L. Cote |
| Federal District |
Southern District of New York |
| MDL Created |
October 2022 |
| Peak Case Count |
Approximately 500+ cases filed |
| Current Federal Status |
All cases dismissed; appeal pending at Second Circuit |
| Oral Arguments |
November 17, 2025 |
| Bellwether Trials |
None scheduled — litigation never reached trial stage |
The Tylenol autism lawsuit hit a major turning point on December 18, 2023. Judge Cote issued a 148-page Daubert ruling excluding all five of the plaintiffs’ expert witnesses on general causation. She found that the experts had cherry-picked evidence and applied a “transdiagnostic analysis” not generally accepted in the scientific community. As a result, the court granted summary judgment on August 20, 2024 and dismissed all pending federal cases.
Plaintiffs appealed to the U.S. Court of Appeals for the Second Circuit. Oral arguments took place on November 17, 2025. Notably, two of the three judges questioned whether the lower court was too aggressive in excluding expert testimony. As of May 2026, the Second Circuit has not yet issued its decision. A reversal would reopen the MDL and move cases toward bellwether trials.
Who Qualifies for the Tylenol Autism Lawsuit?
You might be eligible for the Tylenol autism lawsuit if you used acetaminophen during pregnancy and your child was later diagnosed with autism or ADHD. Typically, plaintiffs must show they used Tylenol or generic acetaminophen products regularly during pregnancy. A formal diagnosis of autism spectrum disorder or ADHD from a qualified medical professional is generally required.
The exposure period covers any pregnancy during which the mother took acetaminophen-containing products. This includes brand-name Tylenol and store-brand equivalents. For example, Walmart’s Equate, CVS Health acetaminophen, and Costco’s Kirkland brand are all included. Evidence that may support a claim includes pharmacy records, medical charts noting acetaminophen use, and diagnostic records for the child.
Not everyone who took acetaminophen during pregnancy will qualify. Attorneys evaluating Tylenol autism lawsuit claims typically look for regular or sustained use rather than occasional doses. They also assess the child’s diagnosis, medical history, and other potential contributing factors. Consulting a licensed attorney is the best way to determine whether your specific situation meets the current filing criteria.
How to File a Tylenol Autism Lawsuit Claim
Filing a Tylenol autism lawsuit claim begins with contacting a mass tort attorney experienced in pharmaceutical litigation. Most firms offer free case evaluations. During this review, the attorney will assess your acetaminophen usage history and your child’s medical records. There is typically no upfront cost because these cases are handled on a contingency fee basis.
If your case is accepted, your attorney will prepare and file a complaint. For federal claims, this means filing in the Southern District of New York where MDL 3043 is consolidated. However, with the federal MDL currently on appeal, some attorneys are filing in state courts instead. You will likely need to complete a plaintiff fact sheet detailing your medical history, product usage, and your child’s diagnosis.
Statutes of limitations vary by state. In most cases, you have two to three years from the date of diagnosis or discovery of the potential link. However, some states have shorter deadlines. Acting promptly is important because missing the filing deadline could permanently bar your claim. An attorney licensed in your state can advise on the applicable time limits.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
Settlement Updates and What to Expect
As of May 2026, no settlements have been reached in the Tylenol autism lawsuit. Settlement negotiations cannot meaningfully proceed until the Second Circuit rules on the pending appeal. If the appellate court reverses Judge Cote’s Daubert ruling, expert testimony would be reinstated. That outcome would significantly increase settlement pressure on the defendants.
If the appeal succeeds, the litigation would likely move to bellwether trial selection. Bellwether trials test representative cases before a jury. Their outcomes typically influence global settlement discussions. Based on similar pharmaceutical MDLs, the timeline from bellwether selection to trial could take 12 to 18 months. Settlement values in mass tort cases involving childhood injuries vary widely depending on severity of diagnosis, strength of evidence, and duration of exposure.
Factors that may affect individual claim value include the severity of the child’s condition, documented proof of acetaminophen use during pregnancy, and the strength of the causal connection. Families should be prepared for a process that could take several years. In the meantime, the September 2025 FDA notice to physicians flagging a possible association between prenatal acetaminophen and autism has added regulatory weight to the plaintiffs’ position.
State-by-State Considerations
State tort reform laws can significantly affect Tylenol autism lawsuit outcomes. Each state has its own statute of limitations, damage caps, and rules for expert testimony. For example, Texas has seen major activity — Attorney General Ken Paxton sued Kenvue and Johnson & Johnson in October 2025 under the Texas Deceptive Trade Practices Act. In February 2026, a Texas judge denied the defendants’ motion to dismiss, allowing that case to proceed.
States with notable plaintiff activity include Texas, Pennsylvania, Florida, Illinois, and California. Some states apply stricter Daubert standards for expert testimony, while others use the more permissive Frye standard. State-level filings have become especially important while the federal MDL is paused on appeal. You can learn more about how your state’s laws may affect your claim by visiting our state-by-state tort reform guide.
Frequently Asked Questions
Is the Tylenol autism lawsuit still active in 2026?
Yes. While the federal MDL cases were dismissed, plaintiffs have appealed to the Second Circuit. Oral arguments were heard in November 2025. State court cases also remain active, particularly in Texas where the attorney general’s lawsuit is proceeding.
How long does a Tylenol autism lawsuit take to resolve?
Mass tort cases typically take several years from filing to resolution. The Tylenol autism lawsuit timeline depends heavily on the Second Circuit’s ruling. If the appeal succeeds, bellwether trials and settlement talks could follow within one to two years. Consulting a licensed attorney can provide a more specific estimate for your situation.
Can I still file a Tylenol autism lawsuit claim?
You may still be able to file depending on your state’s statute of limitations. Many states allow two to three years from the date you discovered or should have discovered the potential link. However, deadlines vary. Speaking with a mass tort attorney promptly is the best way to protect your rights and determine eligibility.
Check If You May Qualify
Mass tort eligibility depends on your specific exposure, injuries, and the state where you live. A licensed mass tort attorney can evaluate your situation at no upfront cost — most work on contingency, meaning you pay nothing unless you recover compensation.
Official Sources & Resources
For verified mass tort and MDL information:
- JPML: jpml.uscourts.gov — official MDL statistics and transfer orders
- DOJ: justice.gov — settlement announcements and press releases
- FDA: fda.gov — drug recalls, warning letters, and safety alerts
- CDC: cdc.gov — health condition data and exposure guidelines
- EPA: epa.gov — environmental contamination data
- Cornell LII: law.cornell.edu — plain-English legal definitions
Content last reviewed May 2026. This is general educational information, not legal advice. If you notice outdated information, please contact us.
Related Guides
Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content. Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.
